Pre-register for QIAGEN Spotlight Theater, April 2 at 12:30 p.m.
Cancer is a highly complex disease and understanding the various alterations that together determine disease onset, progression, recurrence and response to treatment, is of fundamental importance. Deep understanding of the biological mechanisms is needed to deconstruct cancer’s underlying complexity.
Relevant biomarkers can be used as landmarks for navigating this biological complexity anchoring targeted treatment programs. Critical to program success are highly sensitive and specific assays that have tailored data analysis and interpretation. So the comprehensive biomarker profiling studies are an accurate foundation for actionable real-world insights.
12:30 – 12:35 p.m. Introduction to speakers and QIAGEN Cancer Toolbox (Sheryl Elkin CSO, N-of-One)
12:35 – 12:55 p.m. Implementation of a comprehensive NGS Oncology Panel including MSI and TMB signatures (Ravindra Kolhe, MD, PhD. University of Augusta)
12:55 – 1:15 p.m. Novel biomarkers for epithelial ovarian cancer (John A. Martignetti, MD PhD, Mount Sinai Hospital)
1:15 – 1:30 p.m. Understanding innate resistance to anti-PD1 in melanoma with Ingenuity Pathway Analysis (IPA) and OmicSoft (Jean-Noel Billaud PhD, QIAGEN).